US · LAB
Standard BioTools Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- South San Francisco, CA 94080
- Website
- standardbio.com
Price · as of 2025-12-31
$0.94
Market cap 434.56M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $29.77 | +3,082.26% |
| Intrinsic Value(DCF) | $0.57 | -39.07% |
| Graham-Dodd Method(GD) | $0.13 | -86% |
| Graham Formula(GF) | $7.98 | +752.81% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $15.82 | $26.29 | $104.61 | $0.00 | $0.00 |
| 2012 | $19.21 | $33.47 | $46.68 | $0.25 | $0.00 |
| 2013 | $47.81 | $77.14 | $104.74 | $0.71 | $0.00 |
| 2014 | $40.89 | $109.02 | $326.54 | $0.00 | $0.00 |
| 2015 | $7.69 | $20.04 | $1.72 | $0.00 | $0.00 |
| 2016 | $5.03 | $21.36 | $0.00 | $0.00 | $1.25 |
| 2017 | $6.83 | $28.41 | $0.00 | $0.00 | $0.00 |
| 2018 | $11.64 | $26.91 | $0.00 | $0.00 | $0.00 |
| 2019 | $2.98 | $22.99 | $0.00 | $0.00 | $0.00 |
| 2020 | $4.52 | $28.38 | $0.00 | $0.00 | $0.00 |
| 2021 | $3.40 | $20.35 | $0.00 | $0.00 | $0.00 |
| 2022 | $2.00 | $20.31 | $0.00 | $0.00 | $38.31 |
| 2023 | $2.78 | $25.28 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.16 | $30.98 | $0.16 | $0.00 | $0.00 |
| 2025 | $1.10 | $29.77 | $0.00 | $0.13 | $7.98 |
AI valuation
Our deep-learning model estimates Standard BioTools Inc.'s (LAB) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $29.77
- Current price
- $0.94
- AI upside
- +3,082.26%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.57
-39.07% upside
Graham-Dodd
$0.13
-86% upside
Graham Formula
$7.98
+752.81% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LAB | Standard BioTools Inc. | $0.94 | 434.56M | +3,082% | -39% | -86% | +753% | -5.60 | 0.99 | 4.92 | -2.77 | — | 0.99 | 49.86% | -109.34% | -87.77% | -16.72% | -23.68% | -12.69% | 0.07 | -3588.65 | 4.19 | 1.86 | 0.92 | -6154.00% | -5108.00% | -4555.00% | -19.69% | -0.69 | -34.48% | 0.00% | 0.00% | 0.00% | -2.82 | -3.18 | 3.08 | 2.09 |
| ADCT | ADC Therapeutics S.A. | $4.10 | 507.9M | +465% | -82% | — | — | -1.13 | -0.88 | 2.52 | -0.50 | — | -0.88 | 91.60% | -184.44% | -222.83% | 89.97% | 41.28% | -46.65% | -0.61 | -2.60 | 3.82 | 3.37 | 1.25 | -4490.00% | 184.00% | 230.00% | -69.75% | -1.54 | 39.40% | 0.00% | 0.00% | 0.00% | -0.39 | -0.41 | 0.72 | -6.56 |
| AVNS | Avanos Medical, Inc. | $14.10 | 654.51M | +97% | -60% | -93% | — | -8.90 | 0.83 | 0.93 | -20.72 | — | 2.44 | 49.77% | -8.78% | -9.68% | -9.07% | -7.21% | -6.54% | 0.17 | -15.40 | 2.15 | 1.17 | -1.18 | -8288.00% | 195.00% | -4801.00% | 6.64% | 0.45 | 5.05% | 0.00% | 0.00% | 3.58% | -11.17 | 15.96 | 0.98 | 0.98 |
| BVS | Bioventus Inc. | $8.78 | 588.05M | +221% | -58% | — | — | -1890.78 | 4.06 | 1.05 | 22.83 | — | -2.28 | 67.72% | -2.09% | -5.85% | -0.20% | -2.20% | -0.04% | 2.27 | -0.31 | 1.31 | 0.80 | 7.50 | -7912.00% | 1189.00% | 37343.00% | 6.28% | 0.18 | 7.76% | 0.00% | 0.00% | 10.62% | -74.74 | 23.69 | 1.56 | 0.82 |
| CBLL | CeriBell, Inc. | $18.67 | 692.58M | +73% | +350% | — | — | -12.42 | 3.80 | 7.45 | -10.25 | — | 3.82 | 87.89% | -65.57% | -59.97% | -29.21% | -202.59% | -25.36% | 0.14 | -30.90 | 9.73 | 9.08 | 0.33 | -5693.00% | 3609.00% | 1427.00% | -6.27% | -2.13 | -144.22% | 0.00% | 0.00% | 0.00% | -9.04 | -12.70 | 5.93 | 17.63 |
| CGEM | Cullinan Therapeutics, In… | $15.50 | 915.68M | — | — | — | — | -2.79 | 0.79 | — | -0.43 | — | 0.79 | 0.00% | — | — | -32.10% | -214.36% | -30.30% | 0.00 | — | 13.53 | 13.12 | 0.48 | -1572.00% | — | 805.00% | -31.02% | -4.74 | -158.17% | 0.00% | 0.00% | 0.00% | -0.36 | -0.49 | — | 7.79 |
| CTKB | Cytek Biosciences, Inc. | $4.48 | 572.83M | +597% | -46% | — | — | -8.51 | 1.66 | 2.81 | -18.31 | -0.83 | 1.84 | 51.84% | -20.04% | -33.02% | -18.05% | -35.25% | -13.85% | 0.04 | -85.20 | 5.04 | 4.16 | 4.42 | 102798.00% | 52.00% | -14013.00% | -1.55% | -0.06 | -7.65% | 0.00% | 0.00% | 0.00% | -7.88 | -36.31 | 1.58 | 3.49 |
| KIDS | OrthoPediatrics Corp. | $19.17 | 480.73M | +230% | -49% | -91% | — | -11.37 | 1.30 | 1.91 | -55.63 | -373.01 | 2.61 | 73.05% | -12.27% | -16.78% | -11.31% | -8.28% | -8.08% | 0.14 | -4.84 | 5.55 | 2.48 | -3.66 | 305.00% | 1545.00% | -6136.00% | -3.54% | -0.11 | -4.56% | 0.00% | 0.00% | 1.84% | -15.12 | -27.47 | 1.85 | 2.35 |
| SY | So-Young International In… | $3.11 | 410.96M | +89% | -82% | — | — | -1.42 | 0.45 | 0.57 | 2.91 | — | 0.49 | 61.30% | -42.58% | -40.19% | -27.42% | -57.86% | -19.74% | 0.13 | — | 2.74 | 2.24 | 9.06 | -284375.00% | -209.00% | 20752.00% | -10.56% | -0.04 | -8.18% | 5.22% | -7.40% | 15.49% | 0.18 | 1.27 | -0.08 | 0.45 |
| TMCI | Treace Medical Concepts, … | $1.86 | 118.52M | +1,477% | -65% | — | — | -1.78 | 1.20 | 0.49 | -1.64 | -53.40 | 1.56 | 79.81% | -25.46% | -27.74% | -58.94% | -67.77% | -28.95% | 0.16 | -10.18 | 4.31 | 2.95 | -0.08 | 333.00% | 159.00% | -3953.00% | -28.08% | -0.52 | -36.90% | 0.00% | 0.00% | 52.40% | -1.30 | -2.40 | 0.33 | -0.40 |
| VREX | Varex Imaging Corporation | $13.17 | 552.08M | +77% | -64% | — | — | -6.94 | 1.03 | 0.57 | 209.03 | -15.31 | 1.86 | 34.39% | -3.29% | -8.32% | -13.87% | -3.65% | -6.01% | 0.85 | -0.78 | 3.43 | 1.67 | 73.40 | 4530.00% | 414.00% | -784.00% | 3.88% | 0.22 | 2.47% | 0.00% | 0.00% | 9.24% | -26.32 | 38.91 | 0.87 | 1.63 |
About Standard BioTools Inc.
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.
- CEO
- Michael Egholm
- Employees
- 814
- Beta
- 1.33
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.57 ÷ $0.94) − 1 = -39.07% (DCF, example).